JP2007507216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007507216A5 JP2007507216A5 JP2006530273A JP2006530273A JP2007507216A5 JP 2007507216 A5 JP2007507216 A5 JP 2007507216A5 JP 2006530273 A JP2006530273 A JP 2006530273A JP 2006530273 A JP2006530273 A JP 2006530273A JP 2007507216 A5 JP2007507216 A5 JP 2007507216A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- cell
- coding sequences
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 101710114676 E1B 55 kDa protein Proteins 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 101710175001 E1B protein, small T-antigen Proteins 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 230000006801 homologous recombination Effects 0.000 claims 2
- 238000002744 homologous recombination Methods 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP03/50679 | 2003-10-02 | ||
| EP0350679 | 2003-10-02 | ||
| PCT/EP2004/052428 WO2005033320A1 (en) | 2003-10-02 | 2004-10-04 | Packaging cells for recombinant adenovirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007507216A JP2007507216A (ja) | 2007-03-29 |
| JP2007507216A5 true JP2007507216A5 (enExample) | 2007-11-22 |
| JP4749334B2 JP4749334B2 (ja) | 2011-08-17 |
Family
ID=34400432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530273A Expired - Fee Related JP4749334B2 (ja) | 2003-10-02 | 2004-10-04 | 組換えアデノウイルス用パッケージング細胞 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7816104B2 (enExample) |
| EP (1) | EP1670925B1 (enExample) |
| JP (1) | JP4749334B2 (enExample) |
| KR (1) | KR101203817B1 (enExample) |
| CN (2) | CN1863918B (enExample) |
| AU (1) | AU2004278517B2 (enExample) |
| BR (1) | BRPI0414670A (enExample) |
| CA (1) | CA2538025C (enExample) |
| DK (1) | DK1670925T3 (enExample) |
| EA (1) | EA010924B1 (enExample) |
| HR (1) | HRP20130616T1 (enExample) |
| IL (2) | IL174489A (enExample) |
| NZ (1) | NZ545501A (enExample) |
| SI (1) | SI1670925T1 (enExample) |
| WO (1) | WO2005033320A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| EP1670925B1 (en) | 2003-10-02 | 2013-05-01 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
| EP1998804B1 (en) * | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| WO2008134720A2 (en) * | 2007-04-30 | 2008-11-06 | Medtronic, Inc. | Inert dna sequences for efficient viral packaging and methods of use |
| CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| MY170927A (en) | 2011-11-28 | 2019-09-19 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| AP2014007993A0 (en) * | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
| CN110832072B (zh) | 2017-04-21 | 2023-11-07 | 真基因太科公司 | 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法 |
| CN108342362A (zh) * | 2018-01-31 | 2018-07-31 | 武汉枢密脑科学技术有限公司 | 一种用于扩增重组犬腺病毒cav2的稳定细胞系mdck及其构建方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889806A (en) * | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
| US5610053A (en) | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5820868A (en) | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| FI972225A7 (fi) | 1994-11-28 | 1997-07-16 | Genetic Therapy Inc | Vektorit kudosspesifistä replikaatiota varten |
| CA2206683A1 (en) | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
| EP1445322B2 (en) * | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| ATE289354T1 (de) | 1999-04-15 | 2005-03-15 | Crucell Holland Bv | Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| CA2812799C (en) | 2001-07-04 | 2016-01-26 | Chromagenics B.V. | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences |
| WO2003031633A2 (de) * | 2001-10-04 | 2003-04-17 | Probiogen Ag | Adenovirales vektorsystem |
| US7026164B2 (en) | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
| EP1670925B1 (en) | 2003-10-02 | 2013-05-01 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
-
2004
- 2004-10-04 EP EP04791140.9A patent/EP1670925B1/en not_active Expired - Lifetime
- 2004-10-04 BR BRPI0414670-0A patent/BRPI0414670A/pt not_active Application Discontinuation
- 2004-10-04 WO PCT/EP2004/052428 patent/WO2005033320A1/en not_active Ceased
- 2004-10-04 CA CA2538025A patent/CA2538025C/en not_active Expired - Fee Related
- 2004-10-04 AU AU2004278517A patent/AU2004278517B2/en not_active Ceased
- 2004-10-04 JP JP2006530273A patent/JP4749334B2/ja not_active Expired - Fee Related
- 2004-10-04 DK DK04791140.9T patent/DK1670925T3/da active
- 2004-10-04 CN CN2004800286959A patent/CN1863918B/zh not_active Expired - Fee Related
- 2004-10-04 SI SI200432052T patent/SI1670925T1/sl unknown
- 2004-10-04 KR KR1020067006263A patent/KR101203817B1/ko not_active Expired - Fee Related
- 2004-10-04 CN CN2011100542020A patent/CN102174536B/zh not_active Expired - Fee Related
- 2004-10-04 EA EA200600693A patent/EA010924B1/ru not_active IP Right Cessation
- 2004-10-04 NZ NZ545501A patent/NZ545501A/en not_active IP Right Cessation
- 2004-10-04 HR HRP20130616TT patent/HRP20130616T1/hr unknown
-
2006
- 2006-03-20 US US11/384,850 patent/US7816104B2/en not_active Expired - Fee Related
- 2006-03-22 IL IL174489A patent/IL174489A/en active IP Right Grant
-
2010
- 2010-07-14 US US12/804,179 patent/US8114637B2/en not_active Expired - Fee Related
-
2013
- 2013-07-18 IL IL227543A patent/IL227543A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kovesdi et al. | Adenoviral producer cells | |
| Zhang et al. | Role for the adenovirus IVa2 protein in packaging of viral DNA | |
| Schiedner et al. | Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production | |
| CA2477954A1 (en) | Means and methods for the production of adenovirus vectors | |
| WO2004001032A3 (en) | Stable adenoviral vectors and methods for propagation thereof | |
| Wurm et al. | Large-scale transient expression in mammalian cells for recombinant protein production | |
| Imler et al. | Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. | |
| Ostapchuk et al. | Control of adenovirus packaging | |
| JP2007507216A5 (enExample) | ||
| JP2005523730A5 (enExample) | ||
| Gao et al. | Human adenovirus type 35: nucleotide sequence and vector development | |
| JP2009523007A5 (enExample) | ||
| CA2428739A1 (en) | Complementing cell lines | |
| Shenk et al. | Genetic analysis of adenoviruses | |
| US6682929B2 (en) | Adenovector complementing cells | |
| JP2003514526A5 (enExample) | ||
| JP2008518591A5 (enExample) | ||
| Von Seggern et al. | Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein | |
| Ostapchuk et al. | Characterization of Empty adenovirus particles assembled in the absence of a functional adenovirus IVa2 protein | |
| Sussenbach | The structure of the genome | |
| WO2006065827A3 (en) | Cell lines for production of replication-defective adenovirus | |
| Zhang et al. | Getting genetic access to natural adenovirus genomes to explore vector diversity | |
| Ng et al. | Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system | |
| Ng et al. | Yeast recombinase FLP functions effectively in human cells for construction of adenovirus vectors | |
| Catalucci et al. | An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent ΔE1-E2-E3-E4 Ad5 vectors |